Drugs/Drug Classes Archives - Page 4 of 49 - The MASH Podcast

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.

July 22, 2023

S4-33.1 – EASL Congress 2023: Focus on New Nomenclature

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the new NAFLD/NASH nomenclature shared at EASL Congress 2023. The groups outlines what the changes entail and shares practical considerations around how to implement the changes in different settings and with patients.

July 22, 2023

S4-33 – EASL Congress: Nomenclature and More Compelling Presentations

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.

July 19, 2023

S4-32.5 – From the Vault: ILC 2022 Looking Back: Crystal Balling & The Semaglutide Trial

In this conversation From the Vault, panelists discuss implications of the semaglutide cirrhosis late-breaker and share what they anticipate might be different one year from the time of recording from ILC 2022.

July 16, 2023

S4-32.4 – The Potential of NASH Drugs as Adjuvant Therapy

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. This final conversation considers important topics yet to be addressed in the preceding sessions. One of the prevailing themes explored is the potential of NASH drugs as adjuvant therapy.

July 16, 2023

S4-32.3 – Discussing Other Drugs in the Therapeutic Landscape

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group moves on from analysis around resmetirom to discuss other drug classes in the therapeutic landscape.

July 15, 2023

S4-32.2 – Why We Should Develop Deeper Understanding of Liver Volume

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group continues to unpack fresh data on resmetirom, discuss its safety profile and speculate ideas around how the field could benefit from an improved understanding of liver volume dynamics.

July 15, 2023

S4-32.1 – Lead Principle Investigator Stephen Harrison Recaps the MAESTRO-NASH Program for Resmetirom

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA Scientific Sessions. In this conversation, Stephen expounds on newly released Phase 3 MAESTRO-NASH data on resmetirom with powerful notes around endpoints, the study population and other elements critical to the full trial package.

July 15, 2023

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

July 13, 2023

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.

July 12, 2023

Category: Drugs/Drug Classes

All Podcast Categories

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

S4-33.1 – EASL Congress 2023: Focus on New Nomenclature

S4-33 – EASL Congress: Nomenclature and More Compelling Presentations

S4-32.5 – From the Vault: ILC 2022 Looking Back: Crystal Balling & The Semaglutide Trial

S4-32.4 – The Potential of NASH Drugs as Adjuvant Therapy

S4-32.3 – Discussing Other Drugs in the Therapeutic Landscape

S4-32.2 – Why We Should Develop Deeper Understanding of Liver Volume

S4-32.1 – Lead Principle Investigator Stephen Harrison Recaps the MAESTRO-NASH Program for Resmetirom

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Listen Now

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.